<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02900664</url>
  </required_header>
  <id_info>
    <org_study_id>CPDR001X2103</org_study_id>
    <secondary_id>2016-000633-49</secondary_id>
    <nct_id>NCT02900664</nct_id>
  </id_info>
  <brief_title>A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)</brief_title>
  <official_title>Phase Ib, Open-label, Multi-center Study to Characterize the Safety, Tolerability and Pharmacodynamics (PD) of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to combine the PDR001 checkpoint inhibitor with each of four&#xD;
      agents with immunomodulatory activity to identify the doses and schedule for combination&#xD;
      therapy and to preliminarily assess the safety, tolerability, pharmacological and clinical&#xD;
      activity of these combinations.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 23, 2016</start_date>
  <completion_date type="Actual">March 17, 2021</completion_date>
  <primary_completion_date type="Actual">March 17, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of treatment-emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) as a measure of safety</measure>
    <time_frame>Throughout the study at every visit, an average of 1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes between baseline and post-baseline laboratory parameters and vital signs.</measure>
    <time_frame>Baseline and throughout the study at every visit, an average of 1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of dose limiting toxicities (DLTs) of treatment (Escalation only)</measure>
    <time_frame>During the first two cycles; Cycle = 28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of dose interruptions</measure>
    <time_frame>Throughout the study at every visit, an average of 1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose intensities</measure>
    <time_frame>Throughout the study at every visit, an average of 1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Severity of treatment-emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) as a measure of safety</measure>
    <time_frame>Throughout the study at every visit, an average of 1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of dose reductions</measure>
    <time_frame>Throughout the study at every visit, an average of 1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Key secondary: Histopathology of tumor infiltrating lymphocytes (TILs)</measure>
    <time_frame>Baseline and approximately after 2 cycles of treatment and at disease progression; Cycle = 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in electrocardiogram (ECG) parameters</measure>
    <time_frame>Baseline and end of treatment, an average of 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best overall response (BOR)</measure>
    <time_frame>T1: Every 2 cycles until the start of T2. T2: Every 2 cycles until cycle 3 and then every 3 cycles until PD; cycle = 28 days</time_frame>
    <description>T1: treatment period 1 (6 cycles of treatment) T2: treatment period 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS) per irRC and RECIST v1.1</measure>
    <time_frame>T1: Every 2 cycles until the start of T2. T2: Every 2 cycles until cycle 3 and then every 3 cycles until PD; cycle = 28 days</time_frame>
    <description>T1: treatment period 1 (6 cycles of treatment) T2: treatment period 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Free Survival (TFS)</measure>
    <time_frame>T1: Every 2 cycles until the start of T2. T2: Every 2 cycles until cycle 3 and then every 3 cycles until PD; cycle = 28 days</time_frame>
    <description>T1: treatment period 1 (6 cycles of treatment) T2: treatment period 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence and/or concentration of anti-PDR001 antibodies.</measure>
    <time_frame>Cycle 1 through cycle 6 in treatment period 1 and 2 (an average of 1 year)</time_frame>
    <description>T1: treatment period 1 (6 cycles of treatment) T2: treatment period 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentration of PDR001, canakinumab, CJM112</measure>
    <time_frame>Cycle 1 through cycle 6 in treatment period 1 and 2 (an average of 1 year)</time_frame>
    <description>T1: treatment period 1 (6 cycles of treatment) T2: treatment period 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations of trametinib and EGF816</measure>
    <time_frame>Cycle 1 through cycle 6 in treatment period 1 and 2 (an average of 1 year)</time_frame>
    <description>T1: treatment period 1 (6 cycles of treatment) T2: treatment period 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Key secondary: Histopathology of myeloid cell infiltrate by IHC (such as CD8, FoxP3 and myeloid markers as appropriate).</measure>
    <time_frame>Baseline and approximately after 3 cycles of treatment and at disease progression; cycle = 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters (Eg. TMax) of EGF816</measure>
    <time_frame>Cycle 1 through cycle 6 in treatment period 1 and 2 (an average of 1 year)</time_frame>
    <description>T1: treatment period 1 (6 cycles of treatment) T2: treatment period 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters (Eg. TMax) of trametinib</measure>
    <time_frame>Cycle 1 through cycle 6 in treatment period 1 and 2 (an average of 1 year)</time_frame>
    <description>T1: treatment period 1 (6 cycles of treatment) T2: treatment period 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter (Eg. TMax) of PDR001</measure>
    <time_frame>Cycle 1 through cycle 6 in treatment period 1 and 2 (an average of 1 year)</time_frame>
    <description>T1: treatment period 1 (6 cycles of treatment) T2: treatment period 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters (Eg. TMax) of canakinumab</measure>
    <time_frame>Cycle 1 through cycle 6 in treatment period 1 and 2 (an average of 1 year)</time_frame>
    <description>T1: treatment period 1 (6 cycles of treatment) T2: treatment period 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters (Eg. TMax) of CJM112</measure>
    <time_frame>Cycle 1 through cycle 6 in treatment period 1 and 2 (an average of 1 year)</time_frame>
    <description>T1: treatment period 1 (6 cycles of treatment) T2: treatment period 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence and/or concentration of anti-canakinumab antibodies.</measure>
    <time_frame>Cycle 1 through cycle 6 in treatment period 1 and 2 (an average of 1 year)</time_frame>
    <description>T1: treatment period 1 (6 cycles of treatment) T2: treatment period 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence and/or concentration of anti-CJM112 antibodies.</measure>
    <time_frame>Cycle 1 through cycle 6 in treatment period 1 and 2 (an average of 1 year)</time_frame>
    <description>T1: treatment period 1 (6 cycles of treatment) T2: treatment period 2</description>
  </secondary_outcome>
  <number_of_arms>15</number_of_arms>
  <enrollment type="Actual">289</enrollment>
  <condition>Colorectal Cancer, Triple Negative Breast Cancer, NSCLC - Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>PDR001+canakinumab in TNBC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PDR001+CJM112 in TNBC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PDR001+trametinib in TNBC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PDR001+EGF816 in TNBC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PDR001+canakinumab in NSCLC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PDR001+CJM112 in NSCLC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PDR001+ trametinib in NSCLC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PDR001+EGF816 in NSCLC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PDR001+canakinumab in CRC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PDR001+ CJM112 in CRC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PDR001+trametinib in CRC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PDR001+ EGF816 in CRC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>canakinumab in TNBC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>canakinumab in NSCLC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>canakinumab in CRC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PDR001</intervention_name>
    <description>Powder for solution for infusion</description>
    <arm_group_label>PDR001+ CJM112 in CRC</arm_group_label>
    <arm_group_label>PDR001+ EGF816 in CRC</arm_group_label>
    <arm_group_label>PDR001+ trametinib in NSCLC</arm_group_label>
    <arm_group_label>PDR001+CJM112 in NSCLC</arm_group_label>
    <arm_group_label>PDR001+CJM112 in TNBC</arm_group_label>
    <arm_group_label>PDR001+EGF816 in NSCLC</arm_group_label>
    <arm_group_label>PDR001+EGF816 in TNBC</arm_group_label>
    <arm_group_label>PDR001+canakinumab in CRC</arm_group_label>
    <arm_group_label>PDR001+canakinumab in NSCLC</arm_group_label>
    <arm_group_label>PDR001+canakinumab in TNBC</arm_group_label>
    <arm_group_label>PDR001+trametinib in CRC</arm_group_label>
    <arm_group_label>PDR001+trametinib in TNBC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ACZ885</intervention_name>
    <description>Solution for injection</description>
    <arm_group_label>PDR001+canakinumab in CRC</arm_group_label>
    <arm_group_label>PDR001+canakinumab in NSCLC</arm_group_label>
    <arm_group_label>PDR001+canakinumab in TNBC</arm_group_label>
    <arm_group_label>canakinumab in CRC</arm_group_label>
    <arm_group_label>canakinumab in NSCLC</arm_group_label>
    <arm_group_label>canakinumab in TNBC</arm_group_label>
    <other_name>canakinumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CJM112</intervention_name>
    <description>Solution for infusion</description>
    <arm_group_label>PDR001+ CJM112 in CRC</arm_group_label>
    <arm_group_label>PDR001+CJM112 in NSCLC</arm_group_label>
    <arm_group_label>PDR001+CJM112 in TNBC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TMT212</intervention_name>
    <description>Tablets</description>
    <arm_group_label>PDR001+ trametinib in NSCLC</arm_group_label>
    <arm_group_label>PDR001+trametinib in CRC</arm_group_label>
    <arm_group_label>PDR001+trametinib in TNBC</arm_group_label>
    <other_name>trametinib</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EGF816</intervention_name>
    <description>Tablets</description>
    <arm_group_label>PDR001+ EGF816 in CRC</arm_group_label>
    <arm_group_label>PDR001+EGF816 in NSCLC</arm_group_label>
    <arm_group_label>PDR001+EGF816 in TNBC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with advanced/metastatic cancer, with measurable disease as determined by&#xD;
             RECIST version 1.1, who have progressed despite standard therapy or are intolerant to&#xD;
             standard therapy, and for whom no effective therapy is available.&#xD;
&#xD;
        Patients must fit into one of the following groups:&#xD;
&#xD;
          -  Colorectal cancer (CRC) (not mismatch repair deficient by local assay including PCR&#xD;
             and/or immunohistochemistry)&#xD;
&#xD;
          -  Non-small cell lung cancer (NSCLC) (adenocarcinoma)&#xD;
&#xD;
          -  Triple Negative Breast Cancer (TNBC) (D&#xD;
&#xD;
          -  ECOG Performance Status ≤ 2&#xD;
&#xD;
          -  Patient must have a site of disease amenable to biopsy, and be a candidate for tumor&#xD;
             biopsy according to the treating institution's guidelines. Patient must be willing to&#xD;
             undergo a new tumor biopsy at baseline, and again during therapy on this study.&#xD;
&#xD;
          -  Prior therapy with PD-1/PDL-1 inhibitors is allowed provided any toxicity attributed&#xD;
             to prior PD-1- or PD-L1-directed therapy did not lead to discontinuation of therapy.&#xD;
&#xD;
          -  Written informed consent must be obtained prior to any screening procedures other than&#xD;
             procedures performed as part of standard of care.&#xD;
&#xD;
        Other protocol-defined inclusion criteria may apply.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of symptomatic central nervous system (CNS) metastases, or CNS metastases&#xD;
             that require local CNS-directed therapy, or increasing doses of corticosteroids within&#xD;
             the prior 2 weeks.&#xD;
&#xD;
          -  History of severe hypersensitivity reactions to other monoclonal antibodies.&#xD;
&#xD;
          -  Out of range laboratory values for measures of hepatic and renal function,&#xD;
             electrolytes and blood counts&#xD;
&#xD;
          -  Impaired cardiac function or clinically significant cardiac disease.&#xD;
&#xD;
          -  Patients with active, known or suspected autoimmune disease.&#xD;
&#xD;
          -  Human Immunodeficiency Virus infection at screening.&#xD;
&#xD;
          -  Escalation part: Active Hepatitis B (HBV) or Hepatitis C (HCV) virus infection at&#xD;
             screening.&#xD;
&#xD;
        Expansion part: Patients with active HBV or HCV are excluded, excepting those patients&#xD;
        undergoing treatment for HBV or HCV.&#xD;
&#xD;
          -  Malignant disease, other than that being treated in this study.&#xD;
&#xD;
          -  Recent systemic anti-cancer therapy&#xD;
&#xD;
          -  Active infection requiring systemic antibiotic therapy.&#xD;
&#xD;
          -  Patients requiring chronic treatment with systemic steroid therapy, other than&#xD;
             replacement dose steroids in the setting of adrenal insufficiency or treatment with&#xD;
             low, stable dose of steroid (&lt;10mg/ day prednisone or equivalent) for stable CNS&#xD;
             metastatic disease.&#xD;
&#xD;
          -  Patients receiving systemic treatment with any immunosuppressive medication, excepting&#xD;
             the above&#xD;
&#xD;
          -  Use of any live vaccines against infectious diseases (e.g. influenza, varicella,&#xD;
             pneumococcus) within 4 weeks of initiation of study treatment.&#xD;
&#xD;
          -  Participation in an interventional, investigational study within 2 weeks of the first&#xD;
             dose of study treatment.&#xD;
&#xD;
          -  Presence of ≥ CTCAE grade 2 toxicity (except alopecia and ototoxicity, which are&#xD;
             excluded if ≥ CTCAE grade 3) due to prior cancer therapy.&#xD;
&#xD;
          -  Recent use of hematopoietic colony-stimulating growth factors (e.g. G-CSF, GMCSF,&#xD;
             M-CSF)&#xD;
&#xD;
        Additional exclusion criteria for Combination arm PDR001+canakinumab and single-agent&#xD;
        canakinumab&#xD;
&#xD;
          -  Patients with tuberculosis (TB). Note: Patient with latent TB may be eligible based on&#xD;
             the investigator's benefit-risk assessment.&#xD;
&#xD;
          -  Patients who have been infected with HBV or HCV including those with inactive disease.&#xD;
&#xD;
        Additional exclusion criteria for Combination arm PDR001+CJM112&#xD;
&#xD;
          -  Patients with TB. Note: Patient with latent TB may be eligible based on the&#xD;
             investigator's benefit-risk assessment.&#xD;
&#xD;
          -  Patients with history of and/or active inflammatory bowel disease.&#xD;
&#xD;
          -  Active skin or soft tissue infection including cellulitis, erysipelas, impetigo,&#xD;
             furuncle,carbuncle, abscess, or fasciitis.&#xD;
&#xD;
          -  Active candida infection, including mucocutaneous infection or history of invasive&#xD;
             candidiasis.&#xD;
&#xD;
        Additional exclusion criteria for Combination arm PDR001+trametinib&#xD;
&#xD;
          -  Patients with history of retinal vein oclusion.&#xD;
&#xD;
          -  Patients with history of interstitial lung disease or pneumonitis.&#xD;
&#xD;
          -  Patients with cardiomyopathy and/or LVEF &lt; LLN.&#xD;
&#xD;
          -  Impairment of gastrointestinal function or GI disease that may significantly alter the&#xD;
             absorption of oral combination partners.&#xD;
&#xD;
          -  Hemoglobin (Hgb) &lt; 9 g/dL without growth factor or transfusion support&#xD;
&#xD;
          -  Women of child-bearing potential using hormonal contraception, unless an additional&#xD;
             contraception method is also used according to the Mekinist® label.&#xD;
&#xD;
        Additional exclusion criteria for Combination arm PDR001+EGF816&#xD;
&#xD;
          -  NSCLC patients with EGFR mutant tumors.&#xD;
&#xD;
          -  Strong inhibitors and strong inducers of CYP3A4 should not be used concomitantly.&#xD;
&#xD;
          -  Patients with history of interstitial lung disease.&#xD;
&#xD;
          -  Patients who have been infected with HBV or HCV including those with inactive disease.&#xD;
&#xD;
          -  Impairment of gastrointestinal function or GI disease that may significantly alter the&#xD;
             absorption of oral combination partners&#xD;
&#xD;
          -  Patients cannot have received radiotherapy to lung fields within 6 months of study&#xD;
             treatment start.&#xD;
&#xD;
        Other protocol-defined exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center SC-3</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287-0013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Brussels</city>
        <zip>BE-B-1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wilrijk</city>
        <zip>2610</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lyon Cedex</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Paris</city>
        <zip>75231</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toulouse Cedex 9</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Villejuif Cedex</city>
        <zip>94800</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tel Aviv</city>
        <zip>6423906</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rozzano</city>
        <state>MI</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Singapore</city>
        <zip>119228</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Singapore</city>
        <zip>169610</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hospitalet de LLobregat</city>
        <state>Catalunya</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tainan</city>
        <zip>70403</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taoyuan</city>
        <zip>33305</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Singapore</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>May 17, 2016</study_first_submitted>
  <study_first_submitted_qc>September 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2016</study_first_posted>
  <last_update_submitted>April 27, 2021</last_update_submitted>
  <last_update_submitted_qc>April 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CRC</keyword>
  <keyword>TNBC</keyword>
  <keyword>NSCLC (adenocarcinoma)</keyword>
  <keyword>Immunomodulation</keyword>
  <keyword>Biomarkers</keyword>
  <keyword>Bayesian logistic regression model</keyword>
  <keyword>PDR001</keyword>
  <keyword>Immunotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trametinib</mesh_term>
    <mesh_term>Spartalizumab</mesh_term>
    <mesh_term>Nazartinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

